吡非尼酮联合吸入N-乙酰半胱氨酸治疗特发性肺纤维化的随机试验
这项48周、随机、开放标签、多中心3期试验比较吡非尼酮联合吸入N-乙酰半胱氨酸352.4 mg每日两次与单用吡非尼酮在IPF患者中的疗效与耐受性。81例患者1:1随机分组,联合组41例、单药组40例;48周FVC变化率分别为-300 mL和-123 mL(差值-178 mL,95%CI -324至-31 mL;p=0.018)。DLCO、6MWD、PFS及急性加重发生率无显著差异,不良事件发生率相似。结论认为联合治疗可能带来更差结局。
要点
- 联合组48周FVC下降-300 mL,单用吡非尼酮组为-123 mL,差异有统计学意义。
- DLCO、6MWD、PFS及急性加重发生率两组无显著差异。
- 不良事件发生率两组相似,联合治疗可能带来更差结局。
核心结论
- 吸入N-乙酰半胱氨酸联合吡非尼酮治疗IPF可能带来更差结局。
研究设计与样本
- 48周、随机、开放标签、多中心3期试验,比较吡非尼酮联合吸入N-乙酰半胱氨酸352.4 mg每日两次与单用吡非尼酮。
- 81例IPF患者按1:1随机分配,联合组41例,单药组40例。
- 主要终点为FVC年下降率。
主要发现
- 48周FVC变化率联合组为-300 mL,单药组为-123 mL,差值-178 mL(95%CI -324至-31 mL;p=0.018)。
- DLCO连续变化、6MWD、PFS及急性加重发生率两组无显著差异。
- 不良事件发生率联合组为55.9%(19例),单药组为50%(18例),两组相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A randomised controlled trial in Japan showed that inhaled N-acetylcysteine monotherapy stabilised serial decline in forced vital capacity (FVC) in some patients with early idiopathic pulmonary fibrosis (IPF). However, the efficacy and tolerability of combination therapy with an antifibrotic agent and inhaled N-acetylcysteine are unknown. METHODS: This 48-week, randomised, open-label, multicentre phase 3 trial compared the efficacy and tolerability of combination therapy with pirfenidone plus inhaled N-acetylcysteine 352.4 mg twice daily with the results for pirfenidone alone in patients with IPF. The primary end-point was annual rate of decline in FVC. Exploratory efficacy measurements included serial change in diffusing capacity of the lung for carbon monoxide (D LCO) and 6-min walk distance (6MWD), progression-free survival (PFS), incidence of acute exacerbation, and tolerability. RESULTS: 81 patients were randomly assigned in a 1:1 ratio to receive pirfenidone plus inhaled N-acetylcysteine (n=41) or pirfenidone (n=40). The 48-week rate of change in FVC was -300 mL and -123 mL, respectively (difference -178 mL, 95% CI -324--31 mL; p=0.018). Serial change in D LCO, 6MWD, PFS and incidence of acute exacerbation did not significantly differ between the two groups. The incidence of adverse events (n=19 (55.9%) for pirfenidone plus N-acetylcysteine; n=18 (50%) for pirfenidone alone) was similar between groups. CONCLUSIONS: Combination treatment with inhaled N-acetylcysteine and pirfenidone is likely to result in worse outcomes for IPF.
引用
- Sakamoto S, Kataoka K, Kondoh Y, et al. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur Respir J. 2021. PMID: 32703779. doi:10.1183/13993003.00348-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。